← Ramkhamhaeng Hospital overview

Ramkhamhaeng Hospital vs Bangkok Dusit Medical Services: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ramkhamhaeng Hospital Public Company Limited (RAM.BK)

Q3 2026
▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

  • RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.

    This is a major acquisition that directly boosts RAM's financials and growth story.

  • RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.

    This is the actual earnings result that shows the impact of RAM's consolidation strategy.

  • Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.

    This is a key competitive threat that pressures RAM's pricing and profitability.

  • Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.

    This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.

August 2026
▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

  • RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.

    This is a major acquisition that directly boosts RAM's financials and growth story.

  • RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.

    This is the actual earnings result that shows the impact of RAM's consolidation strategy.

  • Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.

    This is a key competitive threat that pressures RAM's pricing and profitability.

  • Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.

    This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.

Latest
▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

  • RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.

    This is a major acquisition that directly boosts RAM's financials and growth story.

  • RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.

    This is the actual earnings result that shows the impact of RAM's consolidation strategy.

  • Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.

    This is a key competitive threat that pressures RAM's pricing and profitability.

  • Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.

    This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.

Bangkok Dusit Medical Services Public Company Limited (BDMS.BK)

Q3 2026
▲3▼1

BDMS Q3 rebound: revenue up, profit record forecast, risks remain

  • Revenue rebound and occupancy recovery After a weak Q2, July revenue jumped 8% and occupancy rebounded to 65%, with August revenue up 10%. Analysts called Q2 the year's low and maintained Buy ratings.

    This is the key new positive development that drove the stock in Q3.

  • Record Q3 profit forecast and higher targets Brokers forecast a record Q3 profit of 4.5–4.6 billion baht and raised price targets to as high as 25 baht, citing medical tourism and an 18.8% September rebound in Middle East revenue.

    This shows analyst optimism and upward revisions that likely supported the stock price.

  • WellEra wellness project adds long-term growth The WellEra wellness project is expected to contribute to long-term growth, expanding BDMS's service offerings and tapping into the growing wellness tourism market.

    This is a new strategic initiative that could drive future growth and investor interest.

  • Bangkok floods threaten Q3 profit Bangkok floods could cut Q3 profit by 0.5–1.5%, posing a risk to the strong recovery and potentially dampening investor sentiment.

    This is a key risk factor that could negatively impact Q3 results and stock performance.

September 2026
▲3▼1

BDMS Q3 profit set to hit record on strong August revenue

  • Record Q3 profit forecast Brokers expect BDMS to report a record quarterly profit of 4.5–4.6 billion baht for Q3 2026, up sharply from Q2, as August revenue growth reached 10%, the first double-digit gain since 2024.

    This is the central new development driving positive sentiment for the period.

  • Broker upgrades and higher targets Multiple brokerages raised their price targets for BDMS, with some going up to 25 baht, and maintained buy ratings, citing the weak baht, medical tourism, and a recovering Middle East patient segment.

    Analyst upgrades directly influence investor expectations and stock price.

  • Middle East patient recovery Middle Eastern patient revenue rose 18.8% in September, signaling a rebound from earlier weakness caused by regional unrest, which had previously dragged down international income.

    This shows a key international segment is recovering, supporting future growth.

  • Flood risk to Q3 profit Bangkok floods could reduce Q3 profit by 0.5–1.5%, posing a short-term risk to earnings, though the impact is expected to be limited.

    This is a new risk factor that could dampen the positive outlook.

Latest
▲4

BDMS Set for Record Q3 Profit as Brokers Turn Bullish

  • Record Q3 profit expected Bualuang Securities expects BDMS to report a record Q3 2026 core profit of 4.6 billion baht, up 7% year-on-year and 42% quarter-on-quarter, driven by flu and COVID season, recovering foreign patients, and a low base from weak Cambodia business. This directly boosts earnings expectations and supports the share price.

    This is the most direct and material new catalyst for BDMS's earnings outlook.

  • Brokers raise targets and recommend buying Multiple brokerages issued buy ratings and target prices for BDMS this period: KKPS at 23.50 baht, Asia Plus at 25.00 baht, LHSEC at 25.00 baht, and Bualuang at 23.00 baht. These recommendations reflect growing confidence and can attract investors, pushing the price up.

    Broker upgrades and buy calls are a key driver of investor sentiment and demand for the stock.

  • Middle East patient recovery Middle Eastern tourist numbers rose 18.8% year-on-year in September, with complex cases returning. BDMS derives about 4% of revenue from this group, but higher-margin cases support profit recovery. This helps offset earlier weakness from Middle East unrest.

    The recovery in foreign patients is a significant revenue and margin driver for BDMS.

  • Flood impact limited, demand rebound expected Brokerages estimate the Bangkok floods will have a minimal impact on BDMS, with only 0.5-1.5% of Q3 profit affected. Postponed checkups are expected to return in October, supporting Q4 revenue. This reassures investors that the flood is not a major threat.

    It removes a potential negative overhang and points to a near-term rebound.

▲4

BDMS Rides Record Q3 Profit Forecasts and Weak-Baht Tailwind

  • Brokers hike targets on record Q3 profit TISCO raised its BDMS target to 24.50 baht and lifted 2026-2028 earnings forecasts by 7-9%. Krungsri and KGI both see a record third-quarter profit near 4.5 billion baht, up sharply from Q2, as revenue growth accelerates to around 9-10%.

    This is the core new reason the stock is moving: analysts now expect a record profit rebound, not just a bottom.

  • August revenue growth hits 10%, first double-digit since 2024 August hospital revenue grew 10% year-on-year, up from 8% in July, the first double-digit growth since early 2024. Thai patients, insured patients and a recovering Middle East segment are all contributing, easing the drag from Cambodia and Middle East unrest seen in Q2.

    It shows the operational recovery is real and broadening, which underpins the higher profit forecasts.

  • Weak baht and Fed hike make BDMS a defensive pick The baht has weakened past 33 per dollar and the Fed raised rates again, pushing bond yields to multi-year highs. Brokers including Pie, KSS and InnovestX name BDMS among value or defensive stocks that benefit from medical tourism and steady domestic revenue.

    It explains the macro force steering new money into BDMS even as the broad market weakens.

  • Wellness push adds long-term growth story KGI notes Thailand's wellness market is worth $42.7 billion and growing 7-10% a year. BDMS aims to lift wellness to 20% of revenue by 2035 from 12% in 2025, with the WellEra project valued at 26.5 billion baht as a long-term driver.

    It gives a structural reason beyond the current profit cycle for why investors are positive on BDMS.

August 2026
▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.